blood dyscrasia

(redirected from dyscrasia)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

blood dyscrasia

[′bləd də′skrāzh·ə]
(medicine)
Obsolete term. Any abnormal condition of the formed elements of blood or of the constituents required for clotting.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
Mentioned in ?
References in periodicals archive ?
The greatest decreases were observed in the plasma cell dyscrasia track (32% pre-PDAT to 0% with PDAT) and the lymphoma track (85% pre-PDAT to 0% with PDAT).
Breast amyloidosis should be included in the differential diagnosis for patients with abnormal breast findings suspicious for malignancy who have concomitant systemic immune disease, hematologic malignancy/disorder such as extranodal marginal zone lymphoma or plasma cell dyscrasia or with known systemic amyloidosis.
History of blood dyscrasia and other hematological disorders were also explored and were found to be normal.
The incidence of plasma cell leukaemia ranges between 2% and 4% of patients with plasma cell dyscrasias. [13]
Clinically, FPEs are mainly used for improving digestion and immune regulation, endocrine dyscrasia improvement, and weight reduction.
Resnick, "Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome.
Waldenstrom's macroglobulinemia (WM) is a plasma cell dyscrasia manifesting as lymphoplasmacytic lymphoma in the bone marrow and monoclonal IgM gammopathy in the blood.
Myeloma cast nephropathy (MCN) is the most common pattern of renal injury found in plasma cell dyscrasia and more specifically multiple myeloma (MM).
Light chain deposition disease (LCDD) affects both the glomeruli and tubules as a result of plasmatic dyscrasia seen in multiple myeloma or Waldenstrom's macroglobulinemia.
* A normocellular microscopical appearance, with no plasma cell dyscrasia, was displayed on the bone marrow aspirate.
This result is in accordance with previous findings that a significant number of patients who have previously experienced neutropenia or agranulocytosis during clozapine therapy will develop a blood dyscrasia on rechallenge.